The poor predictive ability of traditional xenograft mouse models is thought to be a key factor underlying failures of novel cancer drugs in clinical trials. Sharpless and DePinho describe the opportunities and challenges in the application of novel genetically engineered mouse models that more faithfully mimic human cancers, and their potential to improve the success of cancer drug development.
- Norman E. Sharpless
- Ronald A. DePinho
